Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia

General Information

Summary This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived NK cells in patients with relapsed/refractory AML.
Description Acute myelogenous leukemia (AML) is a potentially cur-able disease; 70% of newly diagnosed patients achievecomplete remission with first-line therapy, but prognosisworsens for relapsed disease in both pediatric and adultpatients.C-type lectin-like molecule-1 and cluster of differentiation antigen 33 has attracted the researchers' attention due to its high expression in AML while being absent in normal hematopoietic stem cell. Accumulating evidence have demonstrated CLL-1 or CD33 is an ideal target for AML.
Clinical trials phase Phase 1
Start date (estimated) 2024-04-30
End date (estimated) 2026-08-31
Clinical feature
Label acute myeloid leukemia
Description A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.; OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT06367673
ICTRP weblink
Other study identifiers
Name QH-ZYDC-01
Source weblink
Public contact
Public email
First name He
Last name Huang
Phone + 86-13605714822
City Zhejiang
Sponsors Zhejiang University


Which differentiated cell type is used
Label natural killer cell
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Recruiting
Estimated number of participants 24